Blinatumomab Warning and Precautions
The drug Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 and CD3. This medicine is sold under the brand name Blincyto. Healthcare professionals recommend using this medicine for treating patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Blincyto is supplied in a single-dose vial for intravenous infusion in […]
- Posted by admin
- On February 15, 2023
- 0 Comments
- Read More